当前位置:首页 - 行情中心 - 恩威医药(301331) - 财务分析 - 现金流量表

恩威医药

(301331)

  

流通市值:32.81亿  总市值:32.87亿
流通股本:1.03亿   总股本:1.03亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金424,612,821.23199,425,776.38745,712,774.63566,210,081.19
  收到其他与经营活动有关的现金597,312.85476,026.613,975,507874,897.28
  经营活动现金流入小计425,210,134.08199,901,802.99749,688,281.63567,084,978.47
  购买商品、接受劳务支付的现金138,969,340.0568,744,924.24275,137,935.42193,225,160.17
  支付给职工以及为职工支付的现金95,976,777.6550,309,344.03196,456,475.92148,781,353.45
  支付的各项税费35,206,945.9218,649,415.2480,865,441.460,845,460.61
  支付其他与经营活动有关的现金79,874,909.6437,519,993.99118,308,709.0692,768,526.5
  经营活动现金流出小计350,027,973.26175,223,677.5670,768,561.8495,620,500.73
  经营活动产生的现金流量净额75,182,160.8224,678,125.4978,919,719.8371,464,477.74
二、投资活动产生的现金流量:
  收回投资收到的现金818,200---
  取得投资收益收到的现金2,124,925.621,083,803.963,930,500.342,957,570.43
  处置固定资产、无形资产和其他长期资产收回的现金净额41,100-344,08095,842
  收到的其他与投资活动有关的现金862,466,589.53421,395,523.22953,442,976.79637,550,093.5
  投资活动现金流入小计865,450,815.15422,479,327.18957,717,557.13640,603,505.93
  购建固定资产、无形资产和其他长期资产支付的现金34,208,178.0717,453,732.7350,232,429.9446,088,085.94
  支付其他与投资活动有关的现金870,010,100425,000,0001,018,102,500608,000,000
  投资活动现金流出小计904,218,278.07442,453,732.731,068,334,929.94654,088,085.94
  投资活动产生的现金流量净额-38,767,462.92-19,974,405.55-110,617,372.81-13,484,580.01
三、筹资活动产生的现金流量:
  吸收投资收到的现金--18,363,611.13-
  取得借款收到的现金--241,800,000241,800,000
  筹资活动现金流入平衡项目--00
  筹资活动现金流入小计--260,163,611.13241,800,000
  偿还债务支付的现金5,716,002.98-46,800,00041,800,000
  分配股利、利润或偿付利息支付的现金19,864,786.65828,75056,957,196.0456,097,751.6
  支付其他与筹资活动有关的现金--71,301,845.0772,270,000
  筹资活动现金流出小计25,580,789.63828,750175,059,041.11170,167,751.6
  筹资活动产生的现金流量净额-25,580,789.63-828,75085,104,570.0271,632,248.4
四、汇率变动对现金及现金等价物的影响-25.42-8.6990.3-64.32
五、现金及现金等价物净增加额10,833,882.853,874,961.2553,407,007.34129,612,081.81
  加:期初现金及现金等价物余额289,223,789.55289,223,789.55235,816,782.21235,816,782.21
  期末现金及现金等价物余额300,057,672.4293,098,750.8289,223,789.55365,428,864.02
补充资料:
  净利润38,344,181.25-37,497,544.35-
  资产减值准备-669,701.68-5,384,313.82-
  固定资产和投资性房地产折旧14,448,199.75-28,737,915.69-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧14,448,199.75-28,737,915.69-
  无形资产摊销8,235,187.55-16,476,460.65-
  长期待摊费用摊销2,196,076.4-6,232,115.83-
  处置固定资产、无形资产和其他长期资产的损失263,274.66-263,488.07-
  固定资产报废损失108,565.71-53,861.47-
  财务费用249,893.3--1,589,668.74-
  投资损失-2,818,800.74--3,494,421.27-
  递延所得税-1,791,185.04--1,804,005.3-
  其中:递延所得税资产减少-711,245.97--1,593,051.91-
    递延所得税负债增加-1,079,939.07--210,953.39-
  存货的减少4,609,887.6--12,062,423.34-
  经营性应收项目的减少11,822,549.46--36,426,964.25-
  经营性应付项目的增加-5,503,881.4-12,961,182.47-
  其他5,057,516.38-25,425,884.76-
  现金的期末余额300,057,672.4-289,223,789.55-
  减:现金的期初余额289,223,789.55-235,816,782.21-
  现金及现金等价物的净增加额10,833,882.85-53,407,007.34-
公告日期2025-08-262025-04-212025-04-212024-10-24
审计意见(境内)标准无保留意见
TOP↑